| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb75b0b19820e3833ebdcb31603b242b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate |
2016-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05ec7f3e0be1febd1fba083757be84af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f53ce7d0f65b0857bd30c01e11c7fb44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52a9bac277ef64b27503ac8039ccd893 |
| publicationDate |
2016-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016317506-A1 |
| titleOfInvention |
Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity |
| abstract |
The present inventor has found out that the following criteria enable to ensure an effect for increasing the platelet count while preventing an excessive increase in the platelet count; n “when the platelet count has increased by a certain amount and reached to a sufficient level of the platelet count during administration of a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity, administration of the pharmaceutical composition is discontinued thereafter”. |
| priorityDate |
2012-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |